|Day Low/High||8.35 / 8.70|
|52 Wk Low/High||7.00 / 17.20|
Appointment Strengthens Regulatory, Global Clinical Research and Cardiology Expertise as Company Advances Its Development Pipeline and Executes Against Its Vision 2020
Investors in Cytokinetics Inc saw new options begin trading this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Investors in Cytokinetics Inc saw new options begin trading this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CYTK options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.
The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Cytokinetics Inc , where a total volume of 5,044 contracts has been traded thus far today, a contract volume which is representative of approximately 504,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 104.6% of CYTK's average daily trading volume over the past month, of 482,100 shares.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CHE, CLD, DGII, ETR, GRBK, IMO, IRDM, XOM Downgrades: AMOV, BCRH, CCJ, CYTK, DRQ, DVD, ERIC, ETH, HTLD, RDNT, UNFI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
In trading on Wednesday, shares of Cytokinetics Inc crossed below their 200 day moving average of $13.27, changing hands as low as $12.65 per share. Cytokinetics Inc shares are currently trading off about 5.9% on the day.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Cytokinetics Inc saw new options become available this week, for the May 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Company Earns $10 Million Milestone Payment from Amgen
Effects of Omecamtiv Mecarbil Were Similar in Patients with Ischemic and Non-Ischemic Heart Failure
Investors in Cytokinetics Inc saw new options become available today, for the October 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CYTK options chain for the new October 20th contracts and identified one put and one call contract of particular interest.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.